Product Image

Contributor Information

  • Name Anne Lykkesfeldt
  • Institute Danish Cancer Society

Tool Details

  • Tool name: MCF7/TAMR-7 Cell line
  • Tool type: Cell Lines
  • Tool sub-type: Continuous
  • Parental cell line: MCF7 S0.5
  • Organism: Human
  • Tissue: Breast
  • Cancer type: Breast cancer, tamoxifen-resistant
  • Disease: Cancer
  • Conditional: Yes
  • Description: The MCF7/TAMR-7 Cell line is a breast cancer cell line resistant to tamoxifen.Tamoxifen is by far the most widely used drug for hormone-dependent breast cancer. However, primary or acquired resistance to Tamoxifen severely limits its clinical effectiveness. The MCF7/TAMR-7 cell line is a good model cell to study the signalling pathways, which are the major drivers of tamoxifen-resistant growth.
  • Research area: Cancer ; Drug Discovery & Development

  • For Research Use Only

Target Details

Application Details


  • Format: Frozen
  • Growth medium: 37°C under 5% CO2 in air using phenol red-free DMEM:Ham's F-12 containing 1% fetal bovine serum, 2 mM Glutamax and 6 ng/ml insulin. To maintain high-level resistance, medium was supplemented with Tamoxifen (1 ?M).
  • Shipping conditions: Dry ice


  • Available on request


  •   Hole et al. 2015. Int J Oncol. 46(4):1481-90. PMID: 25625755.
  •   Elias et al. 2015. Oncogene. 34(15):1919-27. PMID: 24882577.
  •   New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane.
  •   Pedersen et al. 2014. Int J Oncol. 45(5):2167-75. PMID: 25175082.
  •   Sorafenib and nilotinib resensitize tamoxifen resistant breast cancer cells to tamoxifen treatment via estrogen receptor a.
  •   Lundqvist et al. 2014. Steroids. 85:30-5. PMID: 24747771.
  •   Gene expression profiling identifies FYN as an important molecule in tamoxifen resistance and a predictor of early recurrence in patients treated with endocrine therapy.
  •   1a,25-dihydroxyvitamin D3 inhibits cell growth and NFB signaling in tamoxifen-resistant breast cancer cells.
  •   Thrane et al. 2013. Breast Cancer Res Treat. 139(1):71-80. PMID: 23609470.
  •   Estrogen receptor a is the major driving factor for growth in tamoxifen-resistant breast cancer and supported by HER/ERK signaling.
  •   Larsen et al. 2012. Int J Oncol. 41(5):1863-70. PMID: 22961366.
  •   Carboplatin treatment of antiestrogen-resistant breast cancer cells.
  •   Frankel et al. 2007. Breast Cancer Res Treat. 104(2):165-79. PMID: 17061041.
  •   Protein Kinase C alpha is a marker for antiestrogen resistance and is involved in the growth of tamoxifen resistant human breast cancer cells.
  •   Berstein et al. 2003. Endocr Relat Cancer. 10(2):267-77. PMID: 12790788.
  •   New approaches to the understanding of tamoxifen action and resistance.